The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

FDA accepts to review Pfizer's NDA for rheumatoid arthritis drug Xeljanz.....           Boehringer's Spiolto Respimat approved in European countries to treat COPD.....           FDA accepts to review Pfizer's NDA for rheumatoid arthritis drug Xeljanz.....           Adaptimmune gets FDA acceptance for IND application for MAGE-A10 T in NSCLC patients.....           Arrowhead begins dosing patients in Phase I trial of ARC-AAT to treat AATD.....           Breckenridge gets final ANDA approval for desvenlafaxine XR tablets.....           R-Japan secures autologous stem cell manufacturing license.....           Medicines Patent Pool expands generic manufacturing network to ramp-pp low cost ARVs production.....           Panther Biotechnology agrees to buy Alchemia Oncology.....           Clovis begins rolling NDA submission to FDA for rociletinib to treat advanced EGFR-mutant NSCLC.....           Teva launches generic Aggrenox capsules in US.....           TES Pharma and EPFL establish R&D collaboration.....           Kite Pharma join forces with Leukemia & Lymphoma Society.....           Biogen and AGTC join forces to develop gene therapies in ophthalmology.....           Drug price increases hit record for Q2, with no sign of slowdown, analysts say.....           Eylea expected to keep delivering for Regeneron as Praluent starts to step up.....           Scientists dig up new evidence linking GSK's Pandemrix with narcolepsy.....           Boehringer gets respiratory boost with batch of Spiolto nods in EU.....           Fast-growing Celgene snaps up Merck's abandoned NJ campus.....           With vet drugs pumping, it's no wonder that pharma's eyeing M&A.....           Novo Nordisk to stop distribution of diabetes drug Tresiba in Germany.....           FDA and NIH grant clearance for VistaGen to initiate AV-101 Phase II MDD trial.....           Santen files IND application with FDA for DE-122 to treat wet AMD.....           Gilead submits NDA to FDA for single tablet regimen R/F/TAF to treat HIV.....           GeoVax secures NIH grant for HIV vaccine program.....           FDA approves Spriaso's NDA for codeine antitussive with anti-histamine.....           RedHill gets two notices of allowance from USPTO covering RHB-104.....           Feds want Novartis to cough up $3.4B in damages, fines in kickback case.....           Sworn to end doc payments by 2016, GSK still shelled out $15M last year.....           Biogen to build $1B plant, add 400 jobs in Switzerland.....           Novo Nordisk pulls Tresiba in Germany on pricing dispute.....           Bad news for AstraZeneca: FDA lays out roadmap for would-be Symbicort copycats.....           Bayer, J&J aim to protect Xarelto's market lead with focus on clinical data.....           Taisho to develop and commercialize Ablynx's rheumatoid arthritis drug ozoralizumab in Japan.....           Oramed begins patient enrollment in Phase IIb oral insulin trial of ORMD-0801.....           Neothetics to evaluate clinical effect of LIPO-202 to reduce central abdominal bulging.....           Aridis gets FDA fast track status for pneumonia drug Aerucin.....           Eolas, AstraZeneca to develop orexin-1 receptor antagonist to treat multiple indications.....           Theravance gets marketing authorization for Vibativ in Russia to treat gram-positive bacterial infections.....           Immune Pharma inks license and research deal with Yissum for AmiKet Nano.....           AMAG Pharma agrees to acquire Cord Blood Registry for $700m.....           Immunovaccine begins Phase I trial with DPX-RSV vaccine.....           Cellular Biomedicine completes acquisition of CD40LGVAX vaccine.....           Medical Marijuana holds investment in AXIM Biotechnologies.....           Nutra Pharma selects Pickwick Capital Partners for strategic advisory services.....           FibroGen receives $120m license payment from AstraZeneca.....           AdverseEvents flags TB reports, blood-disorder cases linked to RA drugs.....           Boehringer charges ahead with sale of U.S. generics biz with bids from Hikma, Mallinckrodt.....           Novartis tests performance pricing for much-anticipated Entresto launch.....           Valeant can have Zoetis, Bayer says. We have our hands full already.....           Allergan to close plant in Iceland, lay off 300.....           Pharma to EU officials: We need 'contingency' supply plans in case of 'Grexit'.....           Novartis agrees to buy Spinifex Pharmaceuticals for more than $200m.....           Cosmederm Bioscience introduces two new steroid-free itch relief products.....           Iroko launches pain drug Tivorbex in US.....           Celgene, Juno to develop new immunotherapies for cancer and autoimmune diseases.....           SteadyMed, Cardiome partner to commercialize PAH drug Trevyent outside US.....           Pfizer to commercialize Tris' dextromethorphan cough syrup under Robitussin brand.....           Anacor makes changes to to Kerydin commercialization agreement.....           BSN medical expand lymphoedema therapy solutions with FarrowMed acquisition.....           BioBlast gets orphan drug status for cabaletta in Europe to teat spinocerebellar ataxia.....           Vitae starts Phase I single ascending dose study of VTP-43742 in autoimmune disorders.....           Immunocore enters into immunotherapy-based clinical trial collaboration with Lilly.....           EMA committee grants positive opinion for Abbvie's Humira to treat hidradenitis suppurativa.....           Bayer's Eylea gets approval in Japan to treat retinal vein occlusion.....           Barda exercises $3m in additional contract funding to develop Aeolus' AEOL 10150 to treat acute radiation syndrome.....           WCCT Global gets large investment from Asian Equity Firm.....           Pro Bono Bio gets $15m to accelerate the global launches of Flexiseq and Sequaderma.....           ProQR begins patient enrollment in Phase Ib trial of QR-010 to treat cystic fibrosis.....           Spyryx gets development award to advance novel therapy for cystic fibrosis.....           EU stands by crackdown on drug spending in Ireland.....           Will Mylan boost its Perrigo bid? New securities filing suggests it won't.....           Tougher regulations force Indian drugmakers to invest or divest.....           More SCOTUS fallout: Appeals court revives Lamictal pay-for-delay fight against GSK, Teva.....           Danny Glover signs up with Avanir to spotlight pseudobulbar affect.....           Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say.....           EMA committee recommends approval of Novartis's multiple myeloma drug Farydak.....           Moberg Pharma to secure Eurostars grant of EUR0.9m.....           EMA committee grants positive opinion for Abbvie's Humira to treat hidradenitis suppurativa.....           Bayer's Eylea gets approval in Japan to treat retinal vein occlusion.....           EMA committee issues positive opinions for Alexion's Strensiq and Kanuma.....           EMA validates Biogen and Sobi's MAA for Alprolix to treat hemophilia B.....           Immune begins two Phase II trials with bertilimumab to treat ulcerative colitis and bullous pemphigoid.....           Novartis scores recommendation from EMA for myeloma drug Farydak.....           Sanofi's Brandicourt faces skeptical unions, anxious shareholders.....           Nurse pleads guilty to taking Insys kickbacks as Subsys marketing probe continues.....           Alexion wins EMA nods for not one but two drugs.....           UPDATED: Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert.....           Siemens, BioNTech to develop new personalized cancer vaccines.....           Novasep strengthens bio-conjugation services with new ADC facility in France.....           Immunovaccine, Incyte to evaluate new immunotherapy combination to treat platinum-sensitive ovarian cancer.....           Immune begins two Phase II trials with bertilimumab to treat ulcerative colitis and bullous pemphigoid.....           EMA validates Amicus' MAA for Galafold to treat Fabry patients.....           EMA committee issues positive opinion for Newron's Sarizotan to treat Rett syndrome.....           NIAAA begins clinical study of gabapentin enacarbil to treat patients with AUD.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Particle Engineering

13 April 2015 - Dublin

The first stage for successful Pharmaceutical formulation

April continued to be a busy month for APS events with a well-attended and successful two-day joint meeting organised with the Synthesis and Solid State Pharmaceutical Centre (SSPC) which brought together many key opinion leaders from academia and industry providing world leading knowledge and case studies in all key aspects around particle engineering.


Latest News
MONDAY, 29 JUNE 2015
How will you benefit from attending this year’s APS International PharmSci Conference?. . . The deadline for the early bird rate of 31st July 2015 is fast approaching. Register now to benefit from discounted rates of £66 for one day and up to £170 for three days. Additional discounts are available for APS members.. What APS International PharmSci offers you?. Network with broad range of scientists from fellow students up to eminent professors from most of the key UK Universities. Learn about the latest innovative science by attending a variety of sessions demonstrating how Pharmaceutical Scientists are striving to improve patient health globally Understand how Pharmaceutical Science is applied in the Industry and what opportunities this might present for you by engaging with representatives from the Pharmaceutical Industry including Pfizer, Astra Zeneca, GSK and BMS.. UK Pharm Sci includes:. A session by the Student Association of the APS (SAPS)on Increasing your employability after your degree. A session by the APS New Scientists Focus Group offering the opportunity for new scientists to present.. Submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance to win an award of £500 as a contribution to turn the best idea into reality. View and discuss posters and hear selected abstracts presented on thepodium. Visit the conference exhibition to see and talk to a range of companies offering the latest testing technologies and learn about career opportunities.. Book now at to be part of this leading Pharmaceutical Sciences Conference and gain an insight into the opportunities within Pharmaceutical Sciences..
5th Annual MIBio Conference
FRIDAY, 26 JUNE 2015
MIBio 2015: Stability of biopharmaceuticals – From molecular interactions to successful products. 21st October 2015, Cripps Court, Magdalene College, Cambridge, UK.. The MIBio conference series engages world leading experts from industry and academia in a discussion on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly and safer therapeutic products. Seven key experts in the field will present during the day on this topic, and, as is traditional in the MIBio series, there will be opportunities for audience participation. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots. We look forward to seeing you at MIBio 2015!. The conference website can be found here: . The MIBio 2015 organising committee is:. Jan Jezek (Arecor). Nicholas J. Darton (Arecor). Tejash Shah (GSK). Stephen Harding (University of Nottingham).
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
The Academy of Pharmaceutical Sciences (APS) and the British Society for Nanomedicine (BSNM) are pleased to present an integrated workshop and conference as an extension to the APS PharmSci conference taking place in Nottingham 7th-9th September. This "deep dive" event will expand on the nanomedicine theme which threads through the main conference programme discussing the challenges for “scale up” & manufacture of nanomedicines. . On Thursday 10th September another full day of talks will present delegates with perspectives on the latest development of nanotherapeutics for Infectious Diseases, Cancer and Neurodegenerative Diseases. For more details, please visit us online here:
Powder Flow 2015: Fundamentals to Applications
The APS joined forces with IchemE and the RCS to promote a one day meeting chaired and organized by Ali Hassanpour (University of Leeds, UK) with a committee consisting of Michael Bradley (University of Greenwich, UK) ;Lyn Daintree (Crystec Pharma, UK) ;Tim Freeman (Freeman Technology, UK) and Philippe Rogueda (Aedestra Ltd.). The meeting revealed the latest science underpinning powder flow and handling. It looked at progress in theoretical fundaments and state-of-the-art measurements in the context of practical applications and case studies. Academic and industrial scientists and engineers active in various areas of powder manufacturing, processing and characterization, particularly powder flow and its industrial applications attended the meeting.. Presentations from this meeting are available here:
Follow us
Upcoming Events
APS 6th International PharmSci Conference 2015
7 - 9 September 2015
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
10 September 2015
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5 - 7 October 2015
APS Board Meeting
13 - 14 October 2015
MIBio 2015: Stability of biopharmaceuticals From molecular interactions to successful products
21 October 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.